We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Rapid Pathogen Detection Tool to Return Results Directly from Whole Blood in Six Hours

By LabMedica International staff writers
Posted on 28 Nov 2023

Sepsis, a severe blood infection, is the primary cause of fatalities in hospitals across the United States. More...

This condition, which arises from a pre-existing infection, triggers a systemic response in the body. Sepsis impacts around 1.7 million adults in the U.S. annually, leading to roughly 350,000 deaths. The Centers for Disease Control and Prevention (CDC) has found that about one-third of hospital deaths involve patients who had sepsis at some point during their stay. Additionally, sepsis is the most expensive condition treated in U.S. hospitals, with annual costs ranging from USD 24 to USD 38 billion. The increasing antibiotic resistance due to overuse or misuse of antibiotics makes treating infections more challenging, potentially leading to higher mortality rates. It is estimated that up to 50% of sepsis patients may die if the infection, especially caused by a resistant pathogen, is not treated with the appropriate antibiotics initially. In response, a new initiative is underway to reduce sepsis-related deaths by equipping physicians with vital information to select the most effective antibiotics for specific bloodstream infections.

Siemens Healthineers (Erlangen, Germany) has contracted with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH, Bethesda, MD, USA) to improve antibiotic treatment for sepsis patients. The partnership is centered on developing an innovative diagnostic tool. This tool, leveraging next-generation sequencing, aims to quickly detect and identify various bacteria and fungi from a blood sample within six hours, while also indicating their probable antibiotic resistance. This three-year project, backed by a USD 5.5 million contract, aims to deliver a prototype that meets an urgent clinical requirement – providing timely, precise antibiotic treatments for patients at risk of death due to sepsis.

"To make a difference for patients, we need to push the boundaries of what we thought was possible through collaborative innovation," said Rangarajan Sampath, PhD, head of the Center for Innovation for Diagnostics at Siemens Healthineers. "The bacteria causing sepsis have become ever more effective in evading generic treatment options and a more targeted, precision antimicrobial approach is critical. It's within our capabilities as diagnostic test manufacturers to bridge this gap and support physicians by providing information they need as quickly as possible to treat their patients more precisely for better outcomes."

Related Links:
Siemens Healthineers 
NIH 


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: A family of molecules could help diagnose and treat breast cancer (Photo courtesy of Shutterstock)

Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer

Despite playing essential roles in tissue development and immune protection, the contribution of proteoglycans in cancer remains poorly understood. Some proteoglycans appear to shield the body from cancer,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.